Avalo Therapeutics AVTX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accrued expenses?
- Avalo Therapeutics (AVTX) reported accrued expenses of $1.75M in Q1 2026.
- How has Avalo Therapeutics's accrued expenses changed year-over-year?
- Avalo Therapeutics's accrued expenses decreased by 1.0% year-over-year, from $1.77M to $1.75M.
- What is the long-term trend for Avalo Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accrued expenses has grown at a 106.1% compound annual growth rate (CAGR), from $111K to $4.13M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.